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 Abstract 
 Background aims. The manufacture of multipotential stromal cell (MSC)-based products is costly; therefore, a rapid evalu-
ation of bone marrow (BM)  ‘ quality ’ with respect to MSC content is desirable. The aim of this study was to develop a rapid 
single-platform assay to quantify MSC in BM aspirates.  Methods . Aspirated MSC were enumerated using the CD45  – /low 
CD271 bright phenotype and AccuCheck counting beads and compared with a classic colony-forming unit – ﬁ broblast (CFU-F) 
assay. The phenotype of CD45  – /low CD271 bright cells was deﬁ ned using a range of MSC (CD73, CD105, CD90) and non-
MSC (CD31, CD33, CD34, CD19) markers. The effect of aspirated BM volume on MSC yield was also determined. 
 Results . CD45  – /low CD271 bright cells had a classic MSC phenotype (CD73    CD105    CD90    ). Their numbers correlated 
positively with CFU-F counted manually ( R   0.81, P   0.001) or using automatic measurements of surface area occupied 
by colonies ( R   0.66,  P   0.001). Simultaneous enumeration of CD34     cells revealed donor variability ranges compatible 
with standard International Society of Hematotherapy and Graft Engineering (ISHGE) protocols. Aspirating larger marrow 
volumes gave a signiﬁ cant several-fold reduction in the frequency of CFU-F and CD45  – /low CD271 bright cells per milliliter. 
Therefore aspirated MSC yields can be maximized through a standardized, low-volume harvesting technique.  Conclusions . 
Absolute quantiﬁ cation of CD45  – /low CD271 bright cells was found to be a reliable method of predicting CFU-F yields in BM 
aspirates. This rapid (  40 min) procedure could be suitable for intra-operative quality control of BM aspirates prior to volume 
reduction/direct injection in orthopedics. In the production of culture-expanded MSC, this assay could be used to exclude 
samples containing low numbers of MSC, resulting in improved consistency and quality of manufactured MSC batches. 
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 Introduction 
 Cell therapy with multipotential stromal cells (MSC) 
is being used increasingly to treat graft-versus-host 
disease (GvHD) (1), ﬁ stulising Crohn disease (2) 
and to regenerate new bone following injury or as 
a result of avascular necrosis (3). Most commonly, 
MSC are manufactured by culture ampliﬁ cation of 
plastic-adherent cells derived from the bone marrow 
(BM). BM MSC numbers as typically procured by 
iliac crest marrow aspiration are low (4) and several 
rounds of culture passaging are commonly needed 
to obtain the required cellular yields for therapy 
applications (5). 
 It is now well recognized that the quality of manu-
factured culture-expanded MSC, in respect to both 
their proliferation and differentiation potentials, is 
linked directly with their  in  vitro cultivation history, 
commonly referred to as MSC  ‘ in vitro age ’ (6,7). 
The latter can be measured using telomere length 
analysis (8); however, the analysis is laborious, time 
consuming and hard to perform in routine clinical 
settings (9). Flow cytometry for CD106, CD146 
and others molecules (10 – 12) and quantitative poly-
merase chain reaction (PCR) for selected potency- 
or senescence-related markers have been proposed 
recently (13); however, further cross-center validation 
is required to establish the potential applicability of 
these approaches (9). 
 One critical parameter that logically determines the 
longevity of manufactured MSC cultures is the num-
ber of native MSC present in the seeded sample (9). 
This is of considerable relevance given the reported 
large donor variability in the MSC frequency of BM 
aspirates (4,14,15). A major factor that is thought to 
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contribute to this variability and potentially very low 
MSC yields relates to the marrow aspiration proce-
dure that inadvertently collects marrow diluted with 
peripheral blood from the marrow sinuses (16). The 
MSC content of BM samples is commonly mea-
sured by the classic colony-forming unit – ﬁ broblast 
(CFU-F) assay (17). As with any other functional 
progenitor assay, it has many disadvantages, including 
long duration (2 weeks), dependence on serum lots 
and plating densities, and considerable subjectivity in 
deﬁ ning and scoring colonies. Furthermore, colony 
sizes are known to differ widely from each other, 
while colony-scoring criteria remain poorly deﬁ ned 
and rarely automated (18). A robust prior knowledge 
of the number of MSC seeded may therefore have 
widespread relevance for MSC manufacture pro-
cesses on an industrial scale, both in terms of quality 
control and cost savings. 
 There is also an increased interest in the direct 
injection of whole BM or BM concentrates in clini-
cal orthopedics (15,19). However, the CFU-F assay 
cannot be used at the outset to predict the injected 
quantity of autologous MSC, which is known to be 
a key factor in fracture repair (15). 
 The principal aim of this study was therefore to 
develop a rapid, automated single-platform assay for 
evaluating the MSC content of BM aspirates prior to 
culture initiation or direct use as therapy. A secondary 
aim was to  ‘ troubleshoot ’ the variability of aspirated 
MSC content and suggest ways to maximize MSC 
yields. To accomplish these aims, we assessed the util-
ity of a BM MSC enumeration assay based on the 
CD45  – /low CD271 bright phenotype (referred to hereaf-
ter as CD271 bright cells) (11,20 – 24). CD271-positivity 
of BM MSC was ﬁ rst suggested by Quirici  et al. (20), 
with this MSC identiﬁ cation technique reﬁ ned further 
based on the inclusion of CD45 as a negative gating 
parameter (21). Gating for CD271 bright cells was pro-
posed by Buhring  et al. (22) and later corroborated 
by Tormin  et al. (24). CD146 and MSCA-1/W8B2, 
other candidate BM MSC markers, are also expressed 
on CD271 bright cells (24,22). As a result of this study, 
we show that MSC can be enumerated easily on a 
volumetric basis based on the CD45  – /low CD271 bright 
phenotype, giving a rapid answer regarding the num-
ber of native MSC in a given aspirated sample. Using 
this approach, we also propose an optimized BM 
harvesting method for the maximization of the MSC 
yield in clinical BM aspiration protocols. 
 Methods 
 Harvest of BM aspirate 
 BM aspirates were obtained from the iliac crest of 
acute trauma patients or patients undergoing elec-
tive orthopedic surgery for metalwork removal; all 
patients had no other underlying disease ( n   28, 
16 males, 12 females, median age 37, range 19 – 85). 
All samples were collected into K 3 EDTA vacu-
ettes using a 10-mL syringe and trocar (Stryker, 
Newbury, UK), both of which were ﬁ rst ﬂ ushed with 
1000 U/mL sodium heparin solution (Leo Pharma, 
Buckinghamshire, UK) to avoid clotting. Normally, 
5 mL BM aspirate were obtained from a single aspi-
ration site; the position of the needle was then altered 
by removal of the trocar and repositioning, ensuring 
that the trocar entered the cortical bone at a different 
angle. This procedure was performed a total of four 
times to give a ﬁ nal volume of 20 mL. 
 To investigate the effect of BM dilution with blood 
on the MSC frequency (dilution studies), the needle 
site and angle were kept constant and an initial draw 
of 5 mL was followed by a 15-mL volume draw from 
the same site, and the two draws were analyzed sepa-
rately. Once collected, BM specimens were kept at 
room temperature (RT) and processed within 4 h of 
collection. The frequency of nucleated cells in BM 
aspirates was measured manually by dilution with 
4% acetic acid and counting on a hemocytometer. 
Ethical permission for this study was obtained from 
the Leeds Teaching Hospital National Health Service 
(NHS) Trust (Leeds, UK). 
 CFU-F assay 
 The CFU-F assay was performed as ﬁ rst described 
by Galotto  et al. (25) and was used to enumer-
ate MSC volumetrically. In this assay, 200  μ L BM 
aspirate were seeded into duplicate 100-mm diam-
eter tissue culture dishes (Corning, New York, NY, 
USA) containing 15 mL non-hematopoietic stem 
cell media (NH media; Miltenyi Biotec, Bisley, UK). 
The cells were incubated at 37 ° C, 5% CO 2 . After 
48 h non-adherent cells were removed by washing 
once with phosphate-buffered saline (PBS; Invitro-
gen, Paisley, UK) and fresh media were added. Sub-
sequently, half media changes were performed twice 
a week for 14 days. At the end of the culture period 
the adherent cells were washed with PBS and ﬁ xed 
with 4% formaldehyde (Fisher Scientiﬁ c, Loughbor-
ough, UK) before staining with 0.5% (v/v) crystal 
violet (Sigma-Aldrich, Dorset, UK). Fibroblastic 
colonies were counted macroscopically as described 
previously (26). 
 Measurements of colony area 
 The total area of dishes covered by cells at the 
end of a CFU-F assay allows indirect evaluation 
of the sample ’ s CFU-F activity, being a cumulative 
measure of both CFU-F number and their average 
proliferative capacity. Because manual counting of 
colonies and their sizes is considered fairly subjective 
  Enumeration of multipotential stromal cells by ﬂ ow cytometry  433
(27), digital measurements of total colony area 
were performed in parallel and correlated with the 
numbers of CD271 bright cells. For this, dishes were 
scanned using an Epson 3590 digital scanner and 
digital images were analyzed using NIS elements 
BR 2.20 imaging software (Nikon, Tokyo, Japan). 
Using NIS elements, the area occupied by colo-
nies was identiﬁ ed based on the intensity of the 
crystal violet stain. Dish area was classiﬁ ed into 
uncolonized and colonized regions and the area 
taken up by each region was calculated. No deter-
mination was made of individual colony size or 
morphology. 
 Cell staining and data acquisition 
for enumeration assay 
 Enumeration of MSC (CD45  – /low CD271 bright cells) 
and hematopoietic progenitors (HP; CD34     ) was 
performed using multiparameter ﬂ ow cytometry. 
AccuCheck ™ counting beads (Invitrogen) were 
used to enable enumeration of all populations to 
be performed on a volumetric basis (i.e. number of 
cells/mL). To perform the staining, 50  μ L BM aspi-
rate were incubated for 15 min at RT with CD45 –
 phycoerythrin (PE) – cyanine dye 7 (Cy7) (BD 
Pharmingen, Oxford, UK), CD271 – allophycocy-
anin (APC) (Miltenyi Biotec) and CD34 – PE (BD 
Pharmingen) at the manufacturer ’ s recommended 
concentrations (Table I). Erythrocytes were then 
lysed with the addition of 2 mL ammonium chlo-
ride solution (168 m M NH 2 Cl, 10 m M KHCO 3 , 
1 m M Ethylenediaminetetraacetic acid (EDTA), 
pH 8.0) containing 0.5  μ g/mL 4,6-diamidino-
2- phenylindole (DAPI) (Sigma) and incubation 
at RT for 10 min. Immediately following red 
cell lysis, 50  μ L AccuCheck counting beads (Invit-
rogen) were added and the cell/bead suspension 
was analyzed immediately using an LSR II ﬂ ow 
cytometer (BD Pharmingen). Centrifugation and 
resuspension of the cell suspension were avoided 
because this would result in inaccurate reporting 
of cell frequency because of loss of cells in the 
centrifuged supernatant. 
 Single-antibody stained and unstained controls 
were used before each experiment to ensure accurate 
spectral compensation, and isotype controls (Table I) 
were used to conﬁ rm the gating position for all cell 
populations studied. A minimum of 250 000 events 
was collected for each sample. The acquisition time 
was dependent on the cellularity of the sample: on 
average samples were acquired in 7 min, 23 s (range 
3:16 – 14:42), with the event rate being set as 2000 
events/s. If more than 5 min were required to col-
lect a sufﬁ cient number of events, the sample was 
remixed to ensure sample homogeneity. In order to 
investigate variability between different CD271 anti-
body clones, three samples were also stained with 
CD271 – PE (Miltenyi Biotec) and NGFR – PE (BD 
Pharmingen) (Table I). 
 Analysis of ﬂ ow cytometry data for enumeration assay 
 Flow cytometry data were analyzed using FACS-
Diva Version 5.02 Becton Dickinson (BD). Beads 
were distinguished from cells based on their size 
and ﬂ uorescent properties, as described in the 
Results. Cell debris was excluded based on for-
ward and side scatter, and dead/dying cells were 
identiﬁ ed by the uptake of DAPI. Cell subsets 
were identiﬁ ed as CD271 bright cells (CD45  – /low 
CD271 bright) and HP (CD45    CD34    ). To calcu-
late the absolute count of the cells of interest per 
milliliter of BM aspirate, the following formula was 
 Table I. Antibody conjugates used for ﬂ ow cytometry. 
Target Flourochrome Clone Manufacturer
Enumeration
CD271 Allophycocyanin (APC) ME20.4-1.H4 Miltenyi Biotec
CD271 R-phycoerythrin (PE) ME20.4-1.H4 Miltenyi Biotec
CD271 R-phycoerythrin (PE) C40-1457 BD Pharmingen
CD34 R-phycoerythrin (PE) 563 BD Pharmingen
CD45 PECy7 HI30 BD Pharmingen
Phenotyping
CD73 R-phycoerythrin (PE) AD2 BD Pharmingen
CD90 R-phycoerythrin (PE) MCA90 Serotec
CD105 R-phycoerythrin (PE) SN6 Serotec
CD31 Fluorescein isothiocyanate (FITC) WM59 Serotec
CD33 Fluorescein isothiocyanate (FITC) HIM3-4 BD Pharmingen
CD19 R-phycoerythrin (PE) HIB19 BD Pharmingen
Isotype controls
IgG1 Fluorescein isothiocyanate (FITC) MOPC-31C BD Pharmingen
IgG1 R-phycoerythrin (PE) MOPC-21 BD Pharmingen
IgG1 Allophycocyanin (APC) IS5-21F5 Miltenyi Biotec
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the  ‘ bead ’ gate (Figure 1A). Subsequent gating was 
performed on  ‘ non-beads ’ (gray) events using scatter 
thresholds to exclude cell debris and cell aggregates, 
respectively (Figure 1B). DAPI was used as a viabil-
ity marker, allowing the exclusion of dead/dying cells 
based on DAPI-positivity (Figure 1C). 
used: number of events of interest/total number of 
bead events   starting concentration of counting 
beads per milliliter. 
 Extended phenotyping of CD45  – /low CD271 bright 
and CD45     CD271 low cells 
 Extended phenotyping with CD73, CD90 and 
CD105 (MSC markers) and CD31, CD33 and CD19 
lineage markers (endothelial/myelo/megacariocytic, 
myeloid and B-lymphoid lineages, respectively) was 
performed to investigate the MSC lineage nature of 
CD271 bright and CD271 low (CD45     CD271 low ) cells 
(Table I). Flow cytometry was performed following 
mononuclear cell (MNC) isolation using Lymphop-
rep (Axis Shield, Dundee, UK). The percentage of 
cells expressing both MSC and lineage markers was 
determined for each population of interest. 
 Statistics 
 The Shapiro – Wilk normality test was used to assess 
the distribution normality and to determine the appro-
priate correlation and signiﬁ cance testing. Friedman ’ s 
two-way analysis of variance by ranks was used to assess 
differences in cell survival during data acquisition. The 
Wilcoxon matched-pairs signed rank test was used to 
detect differences between draw volumes. The Spear-
man rank correlation test was used to measure statisti-
cal dependence as well as to generate a 95% conﬁ dence 
interval of predicted individual values. Statistical signif-
icance was deﬁ ned as  P   0.05. All statistics were calcu-
lated using SPSS ® Version 19. Graphs were generated 
using GraphPad Prism ® Version 5.04. 
 Results 
 Reagent selection and gating strategy for the 
enumeration of CD271 bright cells 
 The advantages of single-platform, lyse-no-wash 
protocols include short duration, elimination of the 
loss of cells through centrifugation and increase in 
accuracy by avoiding variations inherent with the 
use of different cell-counting methods (28). The use 
of ﬂ uorescent counting beads provides an absolute 
count of the cells by measuring the ratio of beads 
and the cells of interest. 
 Given these advantages, an AccuCheck bead-
based single-platform approach was selected, based 
on the additional advantage of AccuCheck beads 
to serve as an internal control for sample mixing 
(because of the presence of two types of beads) 
(Figure 1). In our experiments, beads were ﬁ rst 
discriminated from the cells based on their scatter 
and ﬂ uorescence properties, and enumerated within 
 Figure 1. Gating strategy for the enumeration of CD271 bright cells. 
(A) AccuCheck counting beads are quantiﬁ ed and removed from 
analysis based on emission on the ﬂ uorescence (FL1) channel. (B) 
Cell debris are then removed from the analysis based on forward 
scatter. (C) Dead cells are gated out based on the uptake of DAPI. 
(D) CD271 bright cells are enumerated on a CD45/CD271 dot-plot 
within a simple rectangular gate. (E) Minimal non-speciﬁ c binding 
is observed when an IgG1 isotype control is used instead of 
CD271 antibody. (F) Histogram overlay shows no non-speciﬁ c 
binding of IgG1 to CD271 bright cells (black) in comparison with 
CD45 bright cells (grey). (G, H) Histogram overlays show CD34 
and CD73 expression on CD271 bright cells (black) in comparison 
with CD45 bright cells (grey). 
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The median values of CFU-F/mL and CD271 bright 
cells/mL for the studied cohort were 280 and 7230 
(range 3 – 1503 and 398 – 28210), respectively. The 
line of best ﬁ t suggested that approximately 1 in 17 
CD271 bright cells formed a CFU-F colony in our 
experimental conditions. CFU-F colony assay dishes 
representing specimens with very high and very low 
MSC contents are shown on Figure 2C. 
 The accuracy of rare cell enumeration by ﬂ ow 
cytometry, including measuring CD34    cells, is known 
to increase with the use of multiparameter gating 
and the inclusion of a low-expressed marker along-
side a highly expressed marker. We and others have 
shown previously that BM MSC have a CD45  – /low 
CD271 bright phenotype (21,23,24), conﬁ rming that 
CD45 can serve as a very good  ‘ negative discrimi-
nator ’ . Indeed, using a CD45/CD271 dot-plot data 
display, CD271 bright cells could be easily identified 
and enumerated (Figure 1D). In the course of this 
investigation, the proportion of CD271 bright cells was 
determined using CD271 – APC and CD45 – PE – Cy7, 
based on a basic rectangular gate (Figure 1D), and 
the absolute count of CD271 bright cells per mil-
liliter of BM aspirate was calculated in relation to 
the number of events in the bead gate, as described 
in the Methods. The use of an isotype control antibody 
instead of CD271 – APC showed minimal non-speciﬁ c 
binding (Figure 1E). 
 In the same sample tubes, CD34 – PE was added 
for the simultaneous enumeration of CD34    cells. 
Isotype control IgG1 – PE demonstrated no non-
speciﬁ c binding (Figure 1F). As shown previously 
(29), the CD34 expression of gated CD271 bright 
cells was negligible (Figure 1G). On the other hand, 
CD271 bright cells were uniformly CD73    , conﬁ rming 
their MSC identity at a phenotypic level (Figure 1H). 
The expression of CD73 on CD271 bright cells has 
been shown in several independent investigations 
(22 – 24,29). 
 Linearity and precision of absolute cell counting 
 Comparison of automated and manual cell counts 
conﬁ rmed a direct linear relationship between these 
two counting methods ( R   0.98,  P   0.001; Figure 
2A). The high degree of correlation conﬁ rmed that 
AccuCheck counting beads were a reliable means of 
measuring cell number and also enabled the absolute 
quantiﬁ cation of cells of interest in BM aspirates. 
Additionally, close agreement between automated 
and manual counting techniques conﬁ rmed that the 
chosen gating strategy for removing cell debris was 
effective at segregating debris from intact cells, thus 
reducing the risk of experimental error as a result of 
antibody binding to debris. 
 Correlation between the frequency of CD271 bright 
cells and CFU-F 
 Using BM samples from  n    25 donors, a close lin-
ear relationship was observed between the number 
of CFU-F colonies counted manually after 14 days 
of culture and the number of CD271 bright cells per 
milliliter of aspirate ( R    0.812,  P    0.001; Figure 2B). 
 Figure 2. Quantiﬁ cation of CD271 bright and CD34    cells by ﬂ ow 
cytometry and correlations with CFU-F assay and sample 
cellularity. (A) Correlation between cell counts obtained using a 
hemocytometer (manual, man) and using AccuCheck counting 
beads (automatic, auto). (B) Correlation between the frequency 
of day-14 CFU-F and the frequency of CD271 bright cells per 
milliliter of BM aspirate. (C) Representative CFU-F dishes 
showing a specimen with high (left) and low (right) MSC 
frequency. (D) Correlation between the total CFU-F colony area 
and frequency of CD271 bright cells. (E) Correlation between the 
cellularity of aspirate and the frequency of CD34    cells. (F) 
Correlation between the cellularity of aspirate and frequency of 
CD271 bright cells. (G) Predicting a sample ’ s CFU-frequency based 
on CD271 bright cell enumeration. 
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analysis (a minimum of 100 cells in the CD45  – /low 
CD271 bright gate). To investigate any potential loss of 
cells other than erythrocytes during prolonged data 
acquisition in ammonium chloride-containing buf-
fer, the number of cells that had not taken up DAPI 
was next analyzed step-wise over a 10-min period 
following the initial 10-min incubation to remove 
erythrocytes. The 10-min data collection acquisition 
period was divided into ﬁ ve 2-min intervals and the 
number of cells detected was expressed as a propor-
tion of the total (Figure 3A,B). 
 As seen in Figure 3A, there were no signiﬁ cant dif-
ferences in the proportions of total live cells detected 
during earlier or later periods of data acquisition. This 
indicated that ammonium chloride did not have any 
detrimental effect on total cell viability. The lack of a 
decline in cell acquisition rate at the later time points 
also suggested that cell sedimentation at the bottom of 
a tube during later stages of acquisition was unlikely. 
Similarly, the proportions of CD271 bright cells were 
analyzed, and no signiﬁ cant differences between 
any time-points were observed (Figure 3B). This 
indicated that the detection of CD271 bright cells was 
 The numbers of CD271 bright cells also correlated 
strongly with the total area occupied by CFU-F 
colonies ( R    0.66,  P    0.001; Figure 2D). The 
total area occupied by CFU-F colonies and CFU-F 
colony number correlated very well with each other 
( R    0.86,  P    0.001). 
 Correlation between sample cellularity and the 
frequency of CD34     cells and CD271 bright cells 
 The enumeration of CD34     cells was included in 
our experimental protocol for two reasons: ﬁ rst, as 
a quality control for the CD271 bright cell population 
(Figure 1), and second, to assess the feasibility of 
the enumeration of these two important cells sub-
sets (MSC and HP) in a single tube. Our data on 
the numbers of CD34     cells/mL showed very good 
compatibility with the known ranges obtained using 
International Society of Hematotherapy and Graft 
Engineering (ISHGE) CD34 enumeration protocols 
(median 221/ μ L, range 22 – 749) (30). The CD34     
cell counts correlated very closely with the cellu-
larity of the aspirate ( R    0.937,  P   0.001; Figure 
2E). A signiﬁ cant, but much weaker, correlation was 
observed between sample cellularity and the number 
of CD271 bright cells ( R    0.548,  P   0.001; Figure 
2F). 
 The ability of CD271 bright cell enumeration 
to predict a sample ’ s CFU-F content 
 We next explored the ability of the CD271-based 
enumeration assay to predict a specimen ’ s CFU-F 
content (Figure 2G). The logarithmic data transfor-
mation was used to display better the whole range 
of values (particularly the bottom range) and a 95% 
conﬁ dence interval of predicted individual values was 
calculated to establish a cut-off point for the exclusion 
of specimens with potentially poor CFU-F content 
(  100 CFU-F/mL). As seen in Figure 2G, samples 
with CD271 bright cell values of greater than 10 4 cells/
mL (or 10 cells/ μ L) were 95% likely to produce good 
yields of CFU-F colonies (  100 CFU-F/mL). 
 Overall, these data showed that although the cel-
lularity of an aspirate weakly correlated with its MSC 
content, a more accurate quantiﬁ cation, with a high 
degree of conﬁ dence across the whole spectrum of 
values, was achieved by CD271 bright cell enumeration. 
 Method validation 
 As the CD271 bright population is extremely rare 
(median 0.026%, range 0.001 – 0.100) and the event 
rate was kept to 2000 events/s to avoid blockage of 
the cytometer ﬂ ow cell, up to 10 min were normally 
required to collect a sufﬁ cient number of events for 
 Figure 3. Method validation: sample viability during acquisition 
(A, B) and the use of different antibodies (C – F). Total cells (A) 
or CD271 bright cells (B) detected over ﬁ ve continuous 2-min 
intervals as a proportion of the total respective cells acquired 
during the whole 10-min interval. Similar proportions indicate 
that cells remain viable. Representative ﬂ ow cytometry plots 
showing enumeration of CD271 bright cells on the same sample 
using anti-CD271 clone ME20.4-1.H4 APC (C) or PE conjugate 
(D) and anti-CD271 clone C40-1457 PE conjugate (E). 
Enumeration of CD45  – /low CD73 bright population (F). 
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et al . (24), who documented that CD45     CD271 low 
cells were enriched for HP. In contrast, CD271 bright 
cells had a clear MSC phenotype (Figure 4E). 
 Quality control of BM aspiration 
 A highly reproducible quality-controlled marrow 
aspiration technique is essential for investigation of 
the effect of age and disease on MSC dynamics in 
the marrow. As reported previously, hemodilution of 
BM may be the prime reason for the huge (up to 
500-fold) variability in MSC frequency in aspirated 
marrows (16). In order to examine marrow dilution 
effects further and to optimize the collection of MSC 
in BM aspirates, the frequency of CD271 bright cells in 
the ﬁ rst 5 mL of the aspirate was compared with that 
in the following 15 mL aspirated from the same site 
(Figure 5A). The results demonstrated a signiﬁ cant 
7-fold drop in the frequency of CD271 bright cells in 
the second 15-mL draw fraction (average frequency 
2197 cell/mL,  n    7) compared with the ﬁ rst 5-mL 
not affected by prolonged incubation in ammonium 
chloride. To characterize the intra-assay variability 
of this technique, a single aspirate was split into six 
tubes, which were analyzed consecutively. The coef-
ﬁ cient of variation for the proportion of CD271 bright 
cells was measured at 0.105, indicating a signal to 
noise ratio of approximately 10:1. 
 To assess the effect of different anti-CD271 
antibody conjugates or clones on the detection of 
CD271 bright cells, enumeration data obtained using 
CD271 – APC and CD271 – PE (both from Miltenyi 
Biotec; clone ME20.4-1.H4) were compared with data 
obtained with BD CD271 – PE (clone C40-1457) 
( n    3). Additionally, CD73 – PE was evaluated along-
side CD271 – APC ( n    7 donors). The representa-
tive experiment shown in Figure 3C illustrates the 
very similar results obtained with all three CD271 
antibodies, and no statistical signiﬁ cance was found 
(average values of 4180, 3954 and 4198 cells/mL 
for CD271 – APC, CD271 – PE clone ME20.4-1.
H4 and CD271 – PE clone C40-1457, respectively). 
Data obtained on a subset of samples using CD73 
in combination with CD271 showed slightly higher 
frequencies of CD73 bright cells (median 9933, range 
2711 – 36193 cells/mL) compared with CD271 bright 
cells (median 7637, range 1778 – 28210,  P   0.018). 
The strong correlation between the frequencies of 
CD73 bright and CD271 bright cells ( R    0.964) indi-
cated that CD73 could also be used for MSC enu-
meration in BM aspirates (16), but in our hands the 
CD271-based method provided better discrimination 
and less  ‘ noise ’ . 
 Investigation of the CD271 low cell population 
 Apart from CD271 bright cells, BM aspirates consis-
tently contained a population of CD45     CD271 low 
cells (CD271 low ) (Figure 4). In fact, this population 
was more numerous than CD271 bright cells (median 
frequencies of 0.073 and 0.026%, respectively) 
(Figure 4A). The proportions of CD271 low cells posi-
tively correlated with total sample cellularity ( R   
0.681,  P    0.001; Figure 4B), suggesting that these 
cells were unlikely to originate from blood. 
 When the frequency of CD271 low cells was com-
pared with CFU-F data from the same donors, only a 
weak relationship was found (Figure 4C) and the same 
was observed for the correlation between CD271 low 
cells and CD271 bright cells (Figure 4D). The presence 
of CD45 and the lack of a strong correlation with 
CFU-F indicated that CD271 low cells were most likely 
to be hematopoietic in origin. Indeed, when extended 
phenotyping of CD271 low cells and CD271 bright cells 
was performed in parallel, the non-MSC nature of 
CD45     CD271 low cells was conﬁ rmed (Figure 4E). 
This was consistent with data reported by Tormin 
 Figure 4. Investigation of CD45    CD271 low cell population. (A) 
Representative ﬂ ow cytometry plot showing gating for the CD45    
CD271 low cell population. (B) Correlation between the sample 
cellularity and the proportion of CD271 low cells. (C) Correlation 
between the proportions of CFU-F and CD271 low cells. (D) 
Correlation between CD271 bright and CD271 low cells. (E) 
Expression of MSC and non-MSC speciﬁ c markers on CD271 bright 
cells (white) and CD271 low cells (grey). Values are expressed as a 
percentage of the positive cells above isotype control levels. All 
values are signiﬁ cant at  P   0.05 except for CD19. 
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manufacture, as only quantitatively good batches of 
MSC aspirates would be taken forward in GMP 
settings, thus avoiding waste. 
 A second major implication of this work is its 
relevance to the use of  ‘ minimally manipulated 
MSC ’ for therapy development. The rationale for 
this statement comes from the observations that 
aspirated CFU-F yields as measured in retrospect 
were found to correlate with the healing potential of 
BM concentrates injected directly into fracture sites 
(15). However, the dose of injected MSC could not 
be controlled at the outset as the CFU-F assay takes 
14 days to complete. In contrast, the rapid evaluation 
of the number of MSC in the harvested BM sample 
using the proposed 40-min assay would permit the 
surgeon to determine the yield range and estimate 
the dose of MSC prior to injection. This has sig-
niﬁ cant implications for clinical orthopedics trials 
utilizing uncultured MSC, which could be further 
concentrated by size-ﬁ ltering (31) or using CD271-
based immunomagnetic selection. One-stage therapy 
with uncultured MSC has an additional advantage 
of using freshly procured cells that have not been 
artiﬁ cially  ‘ aged ’ in culture by multiple rounds of 
 in  vitro passaging (9,11). 
 Single-platform approaches utilizing lyse-no-wash 
protocols are commonly used in hematology prac-
tice to enumerate CD34 cells and CD4/CD8 cells 
(28,30,32,33). The correlation between the number 
of HP colonies and the proportions of CD34    cells 
was ﬁ rst published in 1993 (34). Subsequently, the 
ﬂ ow cytometry-based assay for CD34    cells was 
reﬁ ned to take into account sample viability during 
extended storage (32) and the provision of counting 
standards (counting beads or tubes) (28,30,32,33). 
The MSC assay reported in this study takes these 
variables into consideration and, similarly to single-
platform CD34 protocols, allows a direct enumera-
tion of MSC per milliliter or microliter of marrow. 
Of note, the results of this study have conﬁ rmed fully 
that BM MSC are considerably less numerous than 
CD34    HP (16). 
 Using the current experimental system, one in 
17 CD271 bright cells formed a colony in the CFU-F 
assay. This is  c. 2-fold lower compared with observa-
tions using sorted CD271 bright cells obtained by us 
(11,23) but is  c. 2-fold higher compared with data 
obtained by Tormin  et al. (24). The reason for this 
small discrepancy may be explained by different 
media/sera and cell seeding densities used. We addi-
tionally acknowledge that performing the CFU-F 
assay volumetrically by direct plating (25,26) rather 
than by cell density from BM MNC (16,17) could 
have affected MSC clonogenicity  in vitro , because 
of the presence of large numbers of red cells. On 
the other hand, the CFU-F assay based on MNC 
draw (average frequency 14450 cell/mL,  P   0.018). 
The same trends were observed for CFU-F (9-fold, 
 P   0.028; Figure 5B). Representative dot-plots are 
shown on Figure 5C,D. 
 Altogether these data have provided evidence 
that prolonged marrow aspiration from the same site 
yields marrow specimens considerably diluted with 
blood. Collection of the same volume of aspirate is 
therefore essential for investigation of MSC frequency 
in ageing and disease. Finally, in order to maximize 
the number of MSC aspirated from the iliac crest for 
the purpose of MSC expansion or direct one-stage 
therapy, our data suggest that each draw should be 
limited in volume, ideally to no more than 5 mL, at 
a single site. 
 Discussion 
 In this work we have shown that a cytometric assay 
can be used reliably to evaluate and potentially 
predict the frequency of MSC in a BM aspirate. 
This assay is therefore of considerable relevance to 
MSC manufacturing protocols and could be used 
to exclude those BM specimens that have a very 
low initial MSC content and for which industrial-
scale cultivation would result in pre-senescent, 
poor-quality MSC. The exclusion of poor-quality 
BM specimens before cultivation in good manu-
facturing practice (GMP) conditions would reduce 
considerably the variability and improve the qual-
ity of MSC-based therapies. This approach could 
also potentially be relevant for cost savings in MSC 
 Figure 5. Quality control of BM aspiration. A higher number of 
CD271 bright cells/mL (A) or CFU-F/mL (B) was observed in the 
ﬁ rst 5 mL of aspirate compared with the following 15-mL draw. 
Representative ﬂ ow cytometry plots showing the population of 
CD271 bright cells in the ﬁ rst 5-mL draw (C) and the following 
15-mL draw (D). 
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